The Eileen McCallum Trust | Facebook

The Eileen McCallum Trust | Facebook: "The Eileen McCallum Trust Eileen McCallum will be starting next year's Edinburgh Half Marathon which takes place on Sunday 11th April 2011. The charity has taken 50 places and 16 have been allocated to River City cast and crew including Claire Knight, Billy McElhaney, Lisa Gardner, Gary Lamont, Keira Lucchesi and Andy Clark. To see the full lis..."

Recent AVI-4658 trial results have positive outcome - Duchennepedia - Action Duchenne - Fighting for a cure for muscular dystrophy

Recent AVI-4658 trial results have positive outcome - Duchennepedia - Action Duchenne - Fighting for a cure for muscular dystrophy: "Results from the recent AVI-4658 study* have been positive so far and are now awaiting further analysis in America by the sponsor AVI BioPharma. Two families that have participated in the trial in the UK share their experiences."

PTC Therapeutics, Inc. - PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY

PTC Therapeutics, Inc. - PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY: "PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY"

Kennedy Krieger Institute: Kennedy Krieger Institute Launches First Phase II Clinical Trial of Heart Disease Treatment for Duchenne Muscular Dystrophy

Kennedy Krieger Institute: Kennedy Krieger Institute Launches First Phase II Clinical Trial of Heart Disease Treatment for Duchenne Muscular Dystrophy: "Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD). Made possible by a $545,000 grant from Pilot Trials Now, an innovative DMD initiative organized and managed by Charley’s Fund Inc. and The Nash Avery Foundation, with additional support from Pfizer Inc., the study will examine whether Revatio (sildenafil) improves cardiac function for those affected by the most common fatal genetic disorder in the world."

Prosensa receives �7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy - Prosensa

Prosensa receives �7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy - Prosensa: "GSK2402968 (PRO051) is an investigational antisense oligonucleotide which induces exon�skipping of exon 51. The six-month data from the open label Phase IIa extension study in 12�patients with DMD, receiving a weekly 6mg/kg systemic delivery by subcutaneous injection, will�be presented at the 15th International Congress of the World Muscle Society in Japan, October�12-16. The data will be presented by Dr. Nathalie Goemans, MD, from the Department of�Pediatric Neurology, University of Leuven, Belgium."

Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers: "“The preliminary results of this multiple dose study in healthy volunteers confirm and expand upon the encouraging results observed previously in the single dose study of ACE-031,” said Matthew Sherman, MD, Chief Medical Officer of Acceleron. “These data are encouraging as we continue the development of ACE-031 in the ongoing Phase 2 study in patients with�Duchenne Muscular Dystrophy.”"

Beaker

Beaker: "Dr. Pier Lorenzo Puri, associate professor at Sanford-Burnham and Italy’s Dulbecco Telethon Institute, and colleagues are figuring out ways to keep the muscle stem cell pool fresh and ready to regenerate injured or diseased muscle. In a study published today in the journal Cell Stem Cell, they uncover the molecular messengers that translate inflammatory signals into the genetic changes that tell muscle stem cells to differentiate. These findings give the scientists a target to artificially dial the stem cell population up or down, a potential treatment that could�boost muscle regeneration in muscular dystrophy patients.

“Our mission is to improve the lives of these patients and extend their lives until they can benefit from a cure 20 years from now,” says Dr. Puri,� a medical doctor who has worked with many muscular dystrophy patients throughout his career."